The Future of Biomarker Detection

Randox Laboratories has been supplying the world’s leading Contract Research Organisations (CRO), Pharmaceutical and Biotech companies for over 27 years with the ‘tools’ required to develop high quality pharmaceuticals faster, safer and more economically.

Following decades of scientific innovation and discovery, today it is inconceivable that any new drug would be developed without simultaneously looking at a multitude of biomarkers. It is widely accepted that the clinical application of validated biomarkers will revolutionise medicine over the coming years. Already pharmaceuticals are being sold with Pharmacogenomic labeling information related to optimising patient selection and personal dosage, but their role in diagnostics will be even more important.

With this in mind a key focus for Randox is to take any newly discovered biomarkers from the realm of research through to clinical utility, whether in the pharmaceutical industry and clinical trials or the wider healthcare industry. However, the process to successfully validate a biomarker is often just as lengthy and costly as for a drug candidate and key to this process is to provide accurate clinical trial results.

Randox’s Biochip Array Technology has been specifically developed to accelerate this validation process. This award-winning technology offers not only ‘diagnostic grade’ results which can be trusted, but the in-built accuracy, precision and specificity of this platform will greatly assist in study publications, clinical trial results and ultimately biomarker validation.